CSF1R and mature T-cell and NK-cell non-Hodgkin lymphoma: While CSF1R is an attractive therapeutic target in PTCL (44), and JAK inhibitors are highly effective agents in disorders associated with macrophage activation (45), our observations suggest that dual JAK/CSF1R inhibition may be required for optimal LAM depletion in PTCL.